Drug Profile
Rosiglitazone - GlaxoSmithKline
Alternative Names: Avandia; BRL 49653; BRL 49653C; Rosiglitazone extended-release; Rosiglitazone maleate; Rosiglitazone XR; RSG XRLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer Bristol-Myers Squibb; GlaxoSmithKline; GSK
- Class Antidementias; Antihyperglycaemics; Antipsoriatics; Small molecules; Thiazolidinediones
- Mechanism of Action Antioxidants; Peroxisome proliferator-activated receptor agonists; Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
- No development reported Asthma
- Discontinued Alzheimer's disease; Psoriasis; Rheumatoid arthritis
Most Recent Events
- 25 Nov 2013 US FDA removes restrictions for use of rosiglitazone-containing drugs in Type 2 diabetes mellitus in the USA
- 06 Jun 2013 Joint advisory committee to the FDA recommends that rosiglitazone remain available to appropriate patients in USA
- 18 May 2011 The US FDA places further restrictions on rosiglitazone-containing drugs